Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer. Nierengarten MB. Cancer 2024;130:1547-1548.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer. Cancer 2024;130:1547-1548.
PMID: 38604979